Clinical Research Directory
Browse clinical research sites, groups, and studies.
Reliability of Standardized IQ Testing Under Modafinil, Racetam-Class Compounds, Sleep Restriction and Daily Activity
Sponsor: Abdulraheem Mohamed Gouda
Summary
This study examined whether standardized IQ test scores in healthy adults aged 18-35 are stable measures of cognitive ability and evaluated whether standardized cognitive-test performance and response-initiation measures vary across pharmacological and sleep conditions. Seventy healthy volunteers were assessed at seven in-person timepoints over six months, with 25 participants receiving an inert matched preparation and 45 receiving modafinil or one of four racetam-class compounds (oxiracetam, pramiracetam, phenylpiracetam, aniracetam) administered orally before testing. A different standardized instrument was administered at each timepoint to limit item-level recall and practice effects, and change in the placebo group was used as the reference for estimating practice effects. Participants were assessed under both rested and sleep-restricted conditions, two psychologists were present at every administration to code response initiation (hesitation), and physiological state was monitored using a consumer wearable. Psychometric changes were evaluated relative to the standard error of measurement of the instruments and the study's prespecified minimum detectable effect. Response-initiation measures were analysed separately from psychometric scores to evaluate potential effects on response initiation and execution time.
Official title: Testing the Reliability of IQ Tests in Various Populations As a Result of Fluctuating Brain Plasticity, Administered Racetam-Class Drugs, Intelligence Placebos, Daily Energy Levels, and Modafinil
Key Details
Gender
All
Age Range
18 Years - 35 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2026-03-09
Completion Date
2026-09-12
Last Updated
2026-10-01
Healthy Volunteers
Yes
Conditions
Interventions
Modafinil
Administered orally, pre-test, at each of seven assessment sessions over six months. Dose not recorded in the source report.
Oxiracetam
Administered orally, pre-test, at 100, 200 or 300 mg/day across the six-month study period.
Pramiracetam
Administered orally, pre-test, at 100, 200 or 300 mg/day across the six-month study period.
Phenylpiracetam
Administered orally, pre-test, at 100, 200 or 300 mg/day across the six-month study period.
Aniracetam
Administered orally, pre-test, at 100, 200 or 300 mg/day across the six-month study period.
Inert matched preparation (placebo)
Inert matched preparation administered orally, pre-test, at each assessment session.
Sleep restriction
Participants were assessed under both rested and sleep-restricted conditions. Sessions were classified against a predefined sleep-duration threshold, and sleep duration was recorded before each cognitive assessment. The numerical threshold is an outstanding data item in the source report.
Locations (1)
Reserology Research Foundation
London, United Kingdom